Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC Molibresib besylate | 1895049-20-3 | 97.0% | 100 MG
Supplier: Medchemexpress LLC HY13032B100MG
Molibresib besylate is an orally active pan-BET inhibitor. It targets BRD2, BRD3, BRD4, and BRDT, disrupting their interaction with chromatin by occupying acetylated lysine binding sites. This inhibits MYC expression and target gene transcription. It exhibits broad antiproliferative activity, useful for research in acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer, and other advanced refractory solid tumors.
- Disrupts BET protein-chromatin interaction
- Inhibits MYC expression and target gene transcription
- Exhibits broad antiproliferative activity
- Induces growth arrest and downregulates mitosis-related genes
- Upregulates p-ERK1/2 levels
- Shows synergistic effects with MEK inhibitors
- Modulates immune microenvironment and prolongs survival in models
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?